Page last updated: 2024-08-24

irinotecan and pki 587

irinotecan has been researched along with pki 587 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Alsina, M; Braña, I; Britten, CD; Del Conte, G; Ezeh, P; Houk, B; Kern, KA; Leong, S; Pathan, N; Pierce, KJ; Siu, LL; Soares, HP; Tabernero, J; Vermette, J; Wainberg, ZA	1

Trials

1 trial(s) available for irinotecan and pki 587

Article	Year
A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer. Targeted oncology, 2017, Volume: 12, Issue:6 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Diphenylamine; Female; Humans; Irinotecan; Male; Morpholines; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; TOR Serine-Threonine Kinases; Triazines	2017

Article

Year

A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.

Targeted oncology, 2017, Volume: 12, Issue:6

Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Diphenylamine; Female; Humans; Irinotecan; Male; Morpholines; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; TOR Serine-Threonine Kinases; Triazines

2017